Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2147-2154

  Bernabeu, Ignacio ^a   Marazuela, Mónica ^c   Lucas, Tomás ^d   Loidi, Lourdes ^b   Alvarez Escolá, Cristina ^e   Luque Ramírez, Manuel ^c   Fernandez Rodriguez, Eva ^a   Paniagua, Amalia Elisa ^c   Quinteiro, Celsa ^b   Casanueva, Felipe F ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; PRIMER DNA;

ACROMEGALY; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG DOSE TITRATION; FEMALE; GENOTYPE; GILBERT DISEASE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HORMONE BLOOD LEVEL; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; SPAIN; TOXIC HEPATITIS; UNIVERSITY HOSPITAL; CLINICAL TRIAL; DRINKING BEHAVIOR; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE DETECTION; HOMOZYGOTE; LIVER DISEASE; MIDDLE AGED; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; SEXUAL DEVELOPMENT; TATA BOX;

ACROMEGALY; ADULT; AGED; ALCOHOL DRINKING; DNA PRIMERS; FEMALE; GENOTYPE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMAN GROWTH HORMONE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, SOMATOTROPIN; REGRESSION ANALYSIS; SEX CHARACTERISTICS; TATA BOX;

EID: 77952764061     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2547     Document Type: Article

References (35)

1. Verma S, Kaplowitz N 2009 Diagnosis, management and prevention of drug-induced liver injury. Gut 58:1555-1564
2. Strassburg CP, Lankisch TO, Manns MP, Ehmer U 2008 Family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol 82:415-433
3. Strassburg CP 2008 Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9:703-715
4. Burchell B, Hume R 1999 Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 14:960-966 (Pubitemid 29487290)
5. Kiang TK, Ensom MH, Chang TK 2005 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132
6. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, Chowdhury NR.1995 The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175
7. Tukey RH, Strassburg CP, Mackenzie PI 2002 Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446-450
8. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP 2006 Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44:1324-1332
9. Köhle C, Möhrle B, Münzel PA, Schwab M, Wernet D, Badary OA, Bock KW 2003 Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 65:1521-1527
10. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
11. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.NEngl JMed342: 1171-1177
12. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
13. Hodish I, Barkan A 2008 Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 6:324-332 (Pubitemid 351733473)
14. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ 2006 Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213-220
15. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, Stalla G, Strasburger C; German Pegvisomant Observational Study Group 2009 The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3-S10
16. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ 2009 Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:529-533
17. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805-806
18. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691
19. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
20. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646
21. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ 2007 Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601
22. Marazuela M, Lucas T, Alvarez-EscoláC, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I 2009 Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535-542
23. Bernabeu I, Cameselle-Teijeiro J, Casanueva FF, Marazuela M 2009 Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur J Endocrinol 160:869-872
24. Soto Moreno A, Guerrero Vazquez R, Venegas Moreno E, Palma Milla S, Castano JP, Leal Cerro A 2009 Self-limited acute hepatotoxicity caused by pegvisomant. Pituitary 10.1007/s11102-009-0173-3
25. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
26. Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M 2009 The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222-229
27. Tarantino G, Di Minno MN, Capone D 2009 Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 15:2817-2833
28. Gunawan BK, Kaplowitz N 2007 Mechanisms of drug-induced liver disease. Clin Liver Dis 11:459-475, v
29. Russmann S, Kullak-Ublick GA, Grattagliano I 2009 Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16:3041-3053
30. Innocenti F, Grimsley C, Das S, Ramírez J, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A 2002 Haplotype structure of the UDP- glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733
31. Peters WH, te Morsche RH, Roelofs HM 2003 Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J Hepatol 38:3-8
32. Paisley AN, Roberts ME, Trainer PJ 2007 Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 66:723-726
33. Lee WM, Squires Jr RH, Nyberg SL, Doo E, Hoofnagle JH 2008 Acute liver failure: summary of a workshop. Hepatology 47:1401-1415 (Pubitemid 351547926)
34. Andrade RJ, Lucena MI, Kaplowitz N, García-Munoz B, Borraz Y, Pachkoria K, García-Cortés M, Fernández MC, Pelaez G, Rodrigo L, Durán JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yagüe T, Salmerón J, Hidalgo R 2006 Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44:1581-1588
35. Trainer PJ 2009 ACROSTUDY: the first 5 years. Eur J Endocrinol 161: S1, S19-24